Thyroid hormone resistance, generalized, autosomal recessive
diseaseOn this page
Also known as GRTHRefetoff syndromeTHRBthyroid hormone receptor BETAthyroid hormone resistancethyroid hormone resistance syndromethyroid hormone resistance, autosomal recessive
Summary
Thyroid hormone resistance, generalized, autosomal recessive (MONDO:0010131) is a disease with 1 cohort gene.
At a glance
- Cohort genes: 1
- ClinVar variants: 11
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | thyroid hormone resistance, generalized, autosomal recessive |
| Mondo ID | MONDO:0010131 |
| MeSH | C567936 |
| OMIM | 274300 |
| NCIT | C85191 |
| UMLS | C3489796 |
| MedGen | 483749 |
| GARD | 0024711 |
| Is cancer (heuristic) | no |
Also known as: GRTH · Refetoff syndrome · THRB · thyroid hormone receptor BETA · thyroid hormone resistance · thyroid hormone resistance syndrome · thyroid hormone resistance, autosomal recessive · thyroid hormone resistance, generalized, autosomal recessive
Data availability: 11 ClinVar variants · 1 GenCC gene-disease record.
Disease family
Classification path: disease › human disease › disease by body system or component › endocrine system disorder › thyroid gland disorder › inherited thyroid metabolism disease › thyroid hormone resistance syndrome › generalized resistance to thyroid hormone › thyroid hormone resistance, generalized, autosomal recessive
Related subtypes (5): thyroid hormone resistance, generalized, autosomal dominant, thyroid ectopia, athyreosis, thyroid hemiagenesis, thyroid hypoplasia
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
ClinVar germline variants
11 retrieved; paginated sample, class counts are floors:
5 pathogenic, 2 uncertain significance, 1 conflicting classifications of pathogenicity, 1 likely benign, 1 pathogenic/likely pathogenic, 1 benign/likely benign
| ClinVar | Variant (HGVS) | Gene | Classification | Review |
|---|---|---|---|---|
| 12566 | NM_001354712.2(THRB):c.728G>A (p.Arg243Gln) | LOC126806630 | Pathogenic | criteria provided, multiple submitters, no conflicts |
| 12538 | NG_009159.1:g.(?270821)(382671_?)del | THRB | Pathogenic | no assertion criteria provided |
| 12539 | NM_001354712.2(THRB):c.1010_1012del (p.Thr337del) | THRB | Pathogenic | criteria provided, single submitter |
| 12557 | NM_001354712.2(THRB):c.958C>T (p.Arg320Cys) | THRB | Pathogenic | criteria provided, multiple submitters, no conflicts |
| 12558 | NM_001354712.2(THRB):c.1012C>T (p.Arg338Trp) | THRB | Pathogenic | criteria provided, multiple submitters, no conflicts |
| 492912 | NM_001354712.2(THRB):c.803C>G (p.Ala268Gly) | THRB | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 2682094 | NM_001354712.2(THRB):c.803C>A (p.Ala268Asp) | THRB | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 3892652 | NM_001354712.2(THRB):c.148A>C (p.Lys50Gln) | THRB | Uncertain significance | criteria provided, multiple submitters, no conflicts |
| 4279745 | NM_001354712.2(THRB):c.80G>A (p.Trp27Ter) | THRB | Uncertain significance | criteria provided, single submitter |
| 4819971 | NM_001354712.2(THRB):c.137G>A (p.Arg46His) | THRB | Likely benign | criteria provided, single submitter |
| 723156 | NM_001354712.2(THRB):c.175A>G (p.Ile59Val) | THRB | Benign/Likely benign | criteria provided, multiple submitters, no conflicts |
Genes & proteins
Mendelian disease overlap and somatic drivers
GenCC: 4 · Orphanet: 1 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0
GenCC gene–disease validity (cohort genes)
the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.
| Gene | Classification | Inheritance | Disease | Records |
|---|---|---|---|---|
| THRB | Strong | Autosomal dominant | thyroid hormone resistance, generalized, autosomal dominant | 4 |
Orphanet rare-disease linkage (cohort genes)
| Gene | Orphanet ID | Rare disease |
|---|---|---|
| THRB | Orphanet:566243 | Resistance to thyroid hormone due to a mutation in thyroid hormone receptor beta |
Cohort genes → proteins
1 cohort genes, 1 distinct canonical proteins.
Evidence partition
| Subset | Genes |
|---|---|
| multi_evidence | 1 |
Cohort genes (full)
| Symbol | HGNC | Ensembl | UniProt | Name | Evidence |
|---|---|---|---|---|---|
| THRB | HGNC:11799 | ENSG00000151090 | P10828 | Thyroid hormone receptor beta | gencc,clinvar |
Cohort function summary
Lead sentence per gene, UniProt-curated.
| Symbol | Protein name | Function (lead sentence) |
|---|---|---|
| THRB | Thyroid hormone receptor beta | Nuclear hormone receptor that can act as a repressor or activator of transcription. |
Protein-family classification
Druggable: 1 · Difficult: 0 · Unknown: 0 · Druggable fraction: 1.0
Family distribution
Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.
| Family | Genes | Fold | FDR |
|---|---|---|---|
| Nuclear receptor | 1 | 385.9× | 0.003 |
Per-gene assignment
| Symbol | Family | Druggable? | EC | InterPro (top 3) |
|---|---|---|---|---|
| THRB | Nuclear receptor | yes | Nucl_hrmn_rcpt_lig-bd, Znf_hrmn_rcpt, Nuclear_hrmn_rcpt |
Expression context
Cohort genes with no expression data: 0.
1 cohort gene are a single-cell marker in ≥1 SCXA experiment.
Breadth distribution (Bgee present_calls)
| Bucket | Genes |
|---|---|
| narrow (1-5 tissues) | 0 |
| moderate (6-20) | 0 |
| broad (>20) | 1 |
| unknown | 0 |
Top tissues across cohort
| Tissue | Cohort genes |
|---|---|
| Brodmann (1909) area 23 | 1 |
| middle temporal gyrus | 1 |
| tibia | 1 |
Per-gene tissue summary (top 30)
| Symbol | Bgee breadth | FANTOM5 breadth | SCXA | Top tissues |
|---|---|---|---|---|
| THRB | 267 | ubiquitous | marker | Brodmann (1909) area 23, middle temporal gyrus, tibia |
Protein interactions among cohort
Intra-cohort edges: 0.
Hub genes (top 10 by interactor count)
| Symbol | Interactor count |
|---|---|
| THRB | 2,044 |
Structural data
PDB: 1 · AlphaFold-only: 0 · No structure: 0
Cohort genes with PDB structures (top 30)
| Symbol | UniProt | PDB entries |
|---|---|---|
| THRB | P10828 | 34 |
Function
Pathway analysis
Distinct Reactome pathways touched by cohort: 9. Enrichment computed across 1 evidence-associated genes (1 with Reactome annotation).
Pathways by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| Pathway | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| SUMOylation of intracellular receptors | 1 | 335.9× | 0.014 | THRB |
| Nuclear Receptor transcription pathway | 1 | 200.3× | 0.014 | THRB |
| SUMO E3 ligases SUMOylate target proteins | 1 | 178.4× | 0.014 | THRB |
| SUMOylation | 1 | 163.1× | 0.014 | THRB |
| RNA Polymerase II Transcription | 1 | 22.5× | 0.072 | THRB |
| Post-translational protein modification | 1 | 19.2× | 0.072 | THRB |
| Gene expression (Transcription) | 1 | 17.8× | 0.072 | THRB |
| Generic Transcription Pathway | 1 | 15.1× | 0.074 | THRB |
| Metabolism of proteins | 1 | 12.4× | 0.081 | THRB |
GO biological processes by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| GO term | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| female courtship behavior | 1 | 5617.3× | 9e-04 | THRB |
| retinal cone cell apoptotic process | 1 | 5617.3× | 9e-04 | THRB |
| thyroid hormone receptor signaling pathway | 1 | 4213.0× | 9e-04 | THRB |
| positive regulation of thyroid hormone receptor signaling pathway | 1 | 4213.0× | 9e-04 | THRB |
| negative regulation of female receptivity | 1 | 3370.4× | 9e-04 | THRB |
| type I pneumocyte differentiation | 1 | 1532.0× | 0.001 | THRB |
| cellular response to thyroid hormone stimulus | 1 | 1532.0× | 0.001 | THRB |
| retinal cone cell development | 1 | 1404.3× | 0.001 | THRB |
| retinoic acid receptor signaling pathway | 1 | 648.1× | 0.003 | THRB |
| regulation of heart contraction | 1 | 495.6× | 0.003 | THRB |
| mRNA transcription by RNA polymerase II | 1 | 330.4× | 0.004 | THRB |
| DNA-templated transcription | 1 | 224.7× | 0.006 | THRB |
| sensory perception of sound | 1 | 100.9× | 0.012 | THRB |
| cell differentiation | 1 | 29.1× | 0.039 | THRB |
| negative regulation of transcription by RNA polymerase II | 1 | 17.7× | 0.060 | THRB |
| positive regulation of transcription by RNA polymerase II | 1 | 14.9× | 0.067 | THRB |
Therapeutics
Drug target analysis
Approved (phase 4): 1 · Phase ≥3: 1 · Phased (≥1): 1 · Undrugged: 0
Druggability breadth: 1 of 1 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).
Genes with an approved drug
The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.
| Symbol | Example approved molecule |
|---|---|
| THRB | AMINOCAPROIC ACID |
Top cohort targets by molecule count
| Symbol | Molecules | Max phase |
|---|---|---|
| THRB | 117 | 4 |
Drugs targeting cohort genes (top 30)
| Molecule | Max phase | Targets in cohort |
|---|---|---|
| AMINOCAPROIC ACID | 4 | THRB |
| INDIGOTINDISULFONATE | 4 | THRB |
| CHLORMADINONE ACETATE | 4 | THRB |
| AMOXAPINE | 4 | THRB |
| IDARUBICIN | 4 | THRB |
| DYCLONINE HYDROCHLORIDE | 4 | THRB |
| ISOSORBIDE | 4 | THRB |
| CLOMIPRAMINE HYDROCHLORIDE | 4 | THRB |
| CHLORMEZANONE | 4 | THRB |
| PHENOXYBENZAMINE HYDROCHLORIDE | 4 | THRB |
| METHYSERGIDE MALEATE | 4 | THRB |
| LIOTHYRONINE SODIUM | 4 | THRB |
| DYCLONINE | 4 | THRB |
| ROSE BENGAL FREE ACID | 4 | THRB |
| INAMRINONE | 4 | THRB |
| MOLSIDOMINE | 4 | THRB |
| METRONIDAZOLE | 4 | THRB |
| AMILORIDE HYDROCHLORIDE | 4 | THRB |
| ALTRETAMINE | 4 | THRB |
| BISOPROLOL FUMARATE | 4 | THRB |
| ATORVASTATIN | 4 | THRB |
| OXYTETRACYCLINE | 4 | THRB |
| LIOTHYRONINE | 4 | THRB |
| MECLOFENAMATE SODIUM | 4 | THRB |
| DAUNORUBICIN HYDROCHLORIDE | 4 | THRB |
| AMANTADINE HYDROCHLORIDE | 4 | THRB |
| ACETOHEXAMIDE | 4 | THRB |
| DEBRISOQUIN SULFATE | 4 | THRB |
| PHENYTOIN SODIUM | 4 | THRB |
| LEVOTHYROXINE | 4 | THRB |
Bioactivity and enzyme data
Enzyme cohort genes (≥1 EC): 0.
Cohort genes with ChEMBL bioactivity (full, sorted by assay count)
| Symbol | Assays | Type breakdown |
|---|---|---|
| THRB | 169 | Binding:129, Functional:40 |
Cohort genes with high screening signal
≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.
| Symbol | ChEMBL assays |
|---|---|
| THRB | 169 |
Pharmacogenomics
Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.
No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).
Chemical tractability of cohort targets
30 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.
| Compound | Max phase | Cohort target (bioactivity) |
|---|---|---|
| AMINOCAPROIC ACID | 4 | THRB |
| INDIGOTINDISULFONATE | 4 | THRB |
| CHLORMADINONE ACETATE | 4 | THRB |
| AMOXAPINE | 4 | THRB |
| IDARUBICIN | 4 | THRB |
| DYCLONINE HYDROCHLORIDE | 4 | THRB |
| ISOSORBIDE | 4 | THRB |
| CLOMIPRAMINE HYDROCHLORIDE | 4 | THRB |
| CHLORMEZANONE | 4 | THRB |
| PHENOXYBENZAMINE HYDROCHLORIDE | 4 | THRB |
| METHYSERGIDE MALEATE | 4 | THRB |
| LIOTHYRONINE SODIUM | 4 | THRB |
| DYCLONINE | 4 | THRB |
| ROSE BENGAL FREE ACID | 4 | THRB |
| INAMRINONE | 4 | THRB |
| MOLSIDOMINE | 4 | THRB |
| METRONIDAZOLE | 4 | THRB |
| AMILORIDE HYDROCHLORIDE | 4 | THRB |
| ALTRETAMINE | 4 | THRB |
| BISOPROLOL FUMARATE | 4 | THRB |
| ATORVASTATIN | 4 | THRB |
| OXYTETRACYCLINE | 4 | THRB |
| LIOTHYRONINE | 4 | THRB |
| MECLOFENAMATE SODIUM | 4 | THRB |
| DAUNORUBICIN HYDROCHLORIDE | 4 | THRB |
| AMANTADINE HYDROCHLORIDE | 4 | THRB |
| ACETOHEXAMIDE | 4 | THRB |
| DEBRISOQUIN SULFATE | 4 | THRB |
| PHENYTOIN SODIUM | 4 | THRB |
| LEVOTHYROXINE | 4 | THRB |
Druggability pyramid
Cohort genes binned by druggability tier (high → low):
| Tier | Definition | Genes | Symbols |
|---|---|---|---|
| A | Approved (phase 4 drug) | 1 | THRB |
| B | Phased (≥1) drug, not yet approved | 0 | |
| C | Druggable family + PDB, no drug | 0 | |
| D | Druggable family + AlphaFold only, no drug | 0 | |
| E | Difficult family or no structure, no drug | 0 |
Undrugged target profiles
0 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).
Clinical trials & evidence
Clinical trials
Clinical trials: 0.
Related Atlas pages
- Cohort genes: THRB